Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects
|
|
- Priscilla Skinner
- 5 years ago
- Views:
Transcription
1 Aliment Pharmacol Ther 2003; 17: doi: /j x Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects G. V. OHNING, J. H. WALSH, J. R. PISEGNA, A. MURTHYà, J. BARTHà & T. O. G. KOVACS Research and Medical Services, Department of Veteran Affairs, VA GLAHS-West Los Angeles Healthcare Center, and the Department of Medicine, School of Medicine, and CURE/UCLA Digestive Disease Center, University of California, Los Angeles, CA, USA; àeisai Inc., Teaneck, NJ, USA Accepted for publication 19 September 2002 SUMMARY Background: Peptone meal-stimulated gastric acid output is considered to be a reliable means to evaluate drug-mediated inhibition of stimulated gastric acid output, an important measure of the efficacy of the agents such as proton pump inhibitors used to treat acid-related disorders. Aim: To compare the initial and overall inhibitory effects on peptone meal-stimulated gastric acid secretion of rabeprazole and omeprazole, 20 mg, in Helicobacter pylori-negative subjects on the first and eighth days of treatment. Methods: Healthy volunteers (n ¼ 27) were randomized in a single-centre, double-blind, double-dummy, 2 2 cross-over study. Subjects received an oral dose of rabeprazole or omeprazole, 20 mg once daily, for 8 days. After a 2 4-week washout period, subjects were crossed over to receive the other medication for 8 days. Peptone meal-stimulated gastric acid secretion was measured at hours 11 and 23 at baseline and on days 1 and 8 of treatment. Results: On days 1 and 8, rabeprazole demonstrated a significantly greater inhibition of peptone meal-stimulated gastric acid secretion compared with omeprazole at all time points (P < 0.03). Median values of steadystate inhibition on day 1 were statistically significant at hour 23 (rabeprazole 100% vs. omeprazole 74%, P < 0.02). Conclusions: Rabeprazole, 20 mg, demonstrated superior control of peptone meal-stimulated gastric acid secretion compared with omeprazole, 20 mg, after the first dose and after the eighth daily dose. Rabeprazole achieved a more rapid onset of acid inhibition and a greater steady-state reduction in peptone meal-stimulated gastric acid secretion. INTRODUCTION The control of gastric acid secretion is important in the initial and long-term treatment of peptic disorders of the upper gastrointestinal tract, particularly gastro-oesophageal reflux disease. Rabeprazole is a member of the Correspondence to: Dr G. V. Ohning, CURE Digestive Disease Research Center, VA GLAHS-West Los Angeles Healthcare Center, Bldg. 115, Rm 217, Wilshire Blvd., Los Angeles, CA 90073, USA. gohning@ucla.edu Deceased. family of substituted benzimidazole proton pump inhibitors that act by forming a covalent bond to the alpha subunit of H +,K + -adenosine triphosphatase (H +,K + - ATPase), effectively inhibiting gastric acid secretion from the parietal cell. 1 The efficacy of proton pump inhibitors can be expressed by the degree and duration of acid suppression per 24-h period after administration and for the overall duration of treatment. 1 We have previously shown rabeprazole s rapid, potent and long-lasting inhibitory effects on gastric acid secretion in Helicobacter Ó 2003 Blackwell Publishing Ltd 1109
2 1110 G. V. OHNING et al. pylori-positive subjects. 2 In the present study, the effectiveness of rabeprazole was compared with omeprazole in the inhibition of peptone meal-stimulated gastric acid secretion after the initiation of therapy and after 8 days of treatment in H. pylori-negative subjects. We excluded H. pylori-positive subjects because H. pylori infection has been shown to enhance the efficacy of proton pump inhibitor therapy. Peptone meal-stimulated gastric acid secretion was determined by an intragastric titration method. 3 This technique measures gastric acid output during physiological stimulation with nutrients, 4 allowing for the comparison of proton pump inhibition in a clinically relevant and reproducible model of stimulated gastric acid secretion. MATERIALS AND METHODS Subjects The research protocol was reviewed and approved by the University of California Los Angeles Institutional Review Board (IRB ) prior to study initiation, and the study was conducted in compliance with all Board regulations. All subjects gave written informed consent before participating in the study. Thirty subjects were enrolled and 27 completed the study. The subjects were screened for enrollment by complete history and physical examination, clinical laboratory tests and gastric acid analysis within a 4-week period prior to baseline acid secretion measurements (day 0). To qualify, subjects were required to have a peptone meal-stimulated gastric acid secretion rate of 8 mmol/h. All subjects were required to have a negative test for H. pylori by serology and to have no previous history of H. pylori infection. Subjects were excluded from the study if they had a history of gastric surgery, abnormal bleeding, thrombophlebitis, human immunodeficiency virus, hepatitis B or hepatitis C infection, any concurrent illnesses or any pre-existing condition that might interfere with any process of the drug from absorption to excretion, any clinically significant substance abuse or psychiatric risk, known hypersensitivity to omeprazole or rabeprazole or the use of histamine 2 -receptor antagonists, prostaglandin analogues, sucralfate, any proton pump inhibitors or any investigational agent within 30 days of study initiation. Female subjects of child-bearing potential were required to use an acceptable method of birth control and to have a negative pregnancy test result prior to study entry and before each treatment period. Study design This study was a single-centre, randomized, doubleblind, double-dummy, 2 2 cross-over design. In the initial baseline period (day 0), after an 8-h overnight fast, subjects received double placebo oral formulations of the study drugs; only low-fat liquids were allowed for 2 h after placebo dosing, following which subjects ate only low-fat, low-fibre foods. They then fasted for at least 6 h until peptone meal-stimulated gastric acid secretion was measured at hour 11. At hour 12, a standard meal was given, and subjects then fasted from hour 15 to hour 23 (8 h), at which time peptone mealstimulated gastric acid secretion was again measured. The first treatment period was initiated within 2 weeks following the baseline day. Subjects were treated for eight consecutive days with one active and one placebo formulation of the study drugs (rabeprazole and omeprazole). All medications were administered orally every morning. Peptone meal-stimulated gastric acid secretion was measured at hours 11 and 23 post-dose on days 1 and 8 of treatment. As during the baseline day, on each study day, subjects fasted for 8 h prior to dose administration and the hour 23 gastric secretion measurement and for 6 h prior to the hour 11 gastric secretion measurement. After a 2 4-week washout period, subjects entered the cross-over treatment period, during which the same procedures were followed as in the first treatment period. One post-treatment visit was conducted within 2 weeks of completion of the second study period to assess the subjects for adverse events and to obtain an exit physical examination and laboratory testing. Compliance with study drug administration was determined by pill count from the administered blister package. Measurement of peptone meal-stimulated gastric acid secretion Each subject was seated in a slightly recumbent chair, and a double-lumen gastric tube (ANPRO AN10, H.W. Anderson Products Inc., Haw River, NC, USA) was placed and positioned. After gastric tube placement, 600 ml of an 8% peptone meal (adjusted to ph 5.5, 320 mos/l; Bactopeptone, Difco Laboratories Inc., Detroit, MI, USA) was infused by gravity over
3 RABEPRAZOLE IS SUPERIOR IN THE INHIBITION OF ACID SECRETION min. Gastric acid secretion was measured using intragastric titration of acid with standardized 0.1 n sodium hydroxide (EM Science, Gibbstown, NJ, USA) to maintain the intragastric ph at 5.5 for a 1-h period. The gastric contents were continuously sampled using an automatic pipetting machine (Scientific Equipment Products, Baltimore, MD, USA), and the gastric ph was measured and adjusted using an ABU901 Autoburette and PHM290 ph-stat controller (Radiometer America, Copenhagen Instruments, Cleveland, OH, USA). The amount of 0.1 n NaOH added during hour 1 of titration was used to calculate the acid output. Gastric acid outputs per hour were reported as the mean values for the baseline and treatment groups. The mean percentage inhibition of acid secretion for each group was calculated from the percentage inhibition for individual subjects. Statistical methods Statistical analyses were performed using SAS software version 6.12 or higher (SAS Institute, Cary, NC, USA), and all tests performed were two-tailed and conducted at the P 0.05 level of significance. An analysis of variance (anova) appropriate for a 2 2 cross-over study was used for the analysis of continuous variables, and the Cochran Mantel Haentzel test and Fisher s exact test were used for the analysis of categorical variables. Adverse events were assessed by the incidence of treatment of emergent signs and symptoms, and these events were classified by body system class and COSTART (Coding Symbols for a Thesaurus of Adverse Reaction Terms) preferred terminology. RESULTS Subjects Twenty-seven subjects qualified for the study, with 24 completing dosing with rabeprazole and 25 completing omeprazole dosing. The randomized distribution resulted in 11 rabeprazole- and 14 omeprazole-treated subjects during the first drug treatment period, and 13 rabeprazole- and 11 omeprazole-treated subjects during the second drug treatment period. Three subjects discontinued participation for reasons unrelated to the study drug: one subject received only a baseline placebo dose and no active medication; a second subject left after only one dose of rabeprazole during the first treatment period; and Table 1. Subject demographics Characteristic n ¼ 27 Sex, n (%) Male 17 (63.0) Female 10 (37.0) Race, n (%) White 20 (74.1) Black 1 (3.7) Hispanic 3 (11.1) Asian/Pacific Islander 2 (7.4) Other 1 (3.7) Mean age (years) 30.4 Mean weight (kg) 74.8 Mean height (cm) a third subject completed the full omeprazole course of therapy but received no rabeprazole treatment. Four individual measurements were excluded from the intention-to-treat analysis due to equipment failure. Subject demographics are shown in Table 1. Peptone meal-stimulated gastric acid output Rabeprazole reduced peptone meal-stimulated gastric acid secretion, expressed as the mean percentage acid inhibition, to a significantly greater degree than omeprazole at all time points on day 1; reductions were also significantly greater with rabeprazole than with omeprazole on day 8 at all time points. Specifically, after initial dosing on day 1, rabeprazole inhibited peptone meal-stimulated gastric acid secretion by 72% at hour 11 and 64% at hour 23, compared with an inhibition of 49% at hour 11 and 38% at hour 23 for omeprazole (P < 0.03, rabeprazole vs. omeprazole, both time points). On day 8, inhibition with rabeprazole was 88% at hour 11 and 64% at hour 23, whereas omeprazole-treated subjects demonstrated 78% inhibition at hour 11 and 50% inhibition at hour 23 (P < 0.03, rabeprazole vs. omeprazole, both time points). Data were reported as the mean inhibition of gastric acid output for each group calculated from the percentage inhibition for individual subjects (Figure 1). In addition, rabeprazole treatment was shown to result in significantly lower levels of peptone meal-stimulated gastric acid secretion (as measured in mmoles of acid) than omeprazole treatment at all time points on days 1 and 8 (P < 0.015; Table 2). The median values of maximal acid inhibition on day 1 demonstrated that rabeprazole achieved 91% of
4 1112 G. V. OHNING et al. 100 Rabeprazole 20 mg Omeprazole 20 mg 100 Rabeprazole 20 mg Omeprazole 20 mg Mean inhibition (%) Median inhibition (%) Hour 11 Hour 23 Hour 11 Hour 23 Day 1 Day 8 0 Hour 11 Hour 23 Day 1 Figure 1. Comparison of the mean inhibition of peptone mealstimulated gastric acid output for rabeprazole, 20 mg, and omeprazole, 20 mg, at hours 11 and 23 on days 1 and 8 of treatment. The mean inhibition for each group was calculated from the percentage inhibition for individual subjects. Table 2. Mean (± S.E.) peptone meal-stimulated gastric acid secretion (mmoles of acid) on days 1 and 8 of treatment Baseline (1.46) Rabeprazole 6.24 (1.58) Omeprazole (2.01) P < vs. omeprazole. steady-state inhibition at hour 11 and 100% at hour 23. The values for omeprazole were 68% at hour 11 and 74% at hour 23 (Figure 2). The difference was statistically significant at hour 23 (P < 0.02). Adverse events Day 1 Day 8 Hour 11 Hour 23 Hour 11 Hour (1.55) 5.86 (1.18) 9.59 (0.98) (1.39) 2.26 (0.46) 4.50 (0.91) (1.59) 6.28 (1.09) 8.02 (1.11) Both medications were well tolerated, as determined by clinical assessment and laboratory values. No serious adverse events were reported. At least one adverse event occurred in 80% of rabeprazole-treated subjects and 68% of omeprazole-treated subjects. The majority (86%) of the adverse events reported were mild in severity; 14% were considered to be moderate in severity. No subjects discontinued study participation because of an adverse event. Headache was the most commonly Figure 2. Median percentage of maximal inhibition of peptone meal-stimulated gastric acid secretion attained on day 1. Comparison of the percentage of maximal inhibition of rabeprazole, 20 mg, and omeprazole, 20 mg, at hours 11 and 23 on the first day of dosing. reported adverse event by both groups [40% (10/25) of rabeprazole-treated subjects; 32% (8/25) of omeprazole-treated subjects]. Adverse events that were considered to be related to treatment accounted for 45% of the symptoms reported by the rabeprazole group and 44% of those reported by the omeprazole group. DISCUSSION Rabeprazole is a substituted benzimidazole proton pump inhibitor with a potent and long-acting inhibitory effect on gastric acid secretion. Rabeprazole has been shown to have a more rapid onset of action than omeprazole in reducing gastric acidity. 5, 6 We have previously reported the inhibition of gastric acid secretion with rabeprazole in H. pylori-positive subjects. 2 In this study, the efficacy of rabeprazole compared with omeprazole was determined by measuring peptone meal-stimulated gastric acid output in H. pylori-negative subjects immediately after initial treatment and during steady state. Nutrients provide a physiological stimulation of gastric acid secretion, 3 and the use of the peptone meal allows for intragastric titration of acid and the reproducible determination of peptone meal-stimulated gastric acid output. 4 This method provides a reliable and validated measurement of the drug-mediated inhibition of stimulated gastric acid output. Peptone meal-stimulated gastric acid output has been used previously to evaluate the efficacy of omeprazole treatment. The inhibitory effect of omeprazole
5 RABEPRAZOLE IS SUPERIOR IN THE INHIBITION OF ACID SECRETION 1113 demonstrated in the present study is similar to that described in a previous report, which showed 42%, 80% and 92% inhibition of peptone meal-stimulated gastric acid secretion for single doses of 30 mg, 60 mg and 90 mg of omeprazole, respectively. 7 Another trial showed a 90% decrease in 24-h intragastric acidity after 1 week of treatment with 20 mg of omeprazole in patients with duodenal ulcer who received six identical meals spaced at 3-h intervals during waking hours. 8 In the present study, both rabeprazole and omeprazole demonstrated a marked inhibition of peptone mealstimulated gastric acid secretion at hours 11 and 23 on days 1 and 8; however, rabeprazole demonstrated a significantly greater inhibitory effect at all time points compared with omeprazole (Figure 1). The study was designed to measure the inhibition of gastric acid output just prior to the mid-point between daily doses (hour 11), and the antisecretory effect just prior to the next daily dose (hour 23). At hour 11 post-dose, rabeprazole achieved 91% of its maximal inhibitory effect on mealstimulated gastric acid secretion on the first day of treatment (day 1), compared with 68% for omeprazole; at hour 23, the values were 100% and 74% for rabeprazole and omeprazole, respectively, a significant difference (Figure 2). Overall, these data indicate that rabeprazole achieves a significantly greater degree of inhibition of gastric acid secretion after the first dose of medication, and the effect is maintained at steady state during subsequent daily dosing over an 8-day period. These data correlate well with a recent report of rabeprazole-mediated inhibition of gastric acidity, measured by continuous ph monitoring, in patients with clinical gastro-oesophageal reflux disease, in that maximal gastric acid output was rapidly and profoundly inhibited after the first dose of medication. 9 The clinical efficacy and tolerability of rabeprazole have been well documented. Rabeprazole, 20 mg, has been shown to be highly efficacious in healing gastric ulcers, duodenal ulcers and gastro-oesophageal reflux disease in a report of three multicentre studies. 10 In a European multicentre study of 103 patients at 25 sites, rabeprazole, 20 mg, and omeprazole, 20 mg, were evaluated in the treatment of duodenal ulcer. After 4 weeks of treatment, a similar rate of ulcer healing was achieved with rabeprazole (98%) and omeprazole (93%); however, rabeprazole-treated subjects reported significantly greater improvements in daytime pain than did omeprazole-treated subjects (P < 0.05; all other symptomatic parameters were comparable in both groups). Initially, mean changes from baseline in fasting serum gastrin were significantly greater in the rabeprazole group; however, the mean values at the end-point were within normal limits for both groups. Both drugs showed good tolerability. 11 A very recent investigation comparing rabeprazole, 20 mg, and esomeprazole, 20 mg, showed that, on a milligram-permilligram basis, rabeprazole increased the 24-h ph on day 1 of dosing to a greater degree than did esomeprazole in healthy subjects, 12 although at standard doses in patients with symptoms of gastro-oesophageal reflux disease an opposite finding has been reported. 13 These and other studies demonstrate that rabeprazole is safe and well tolerated, with a favourable risk/benefit profile. 14 Rabeprazole has the highest pk a value of the proton pump inhibitors and is therefore the least stable at neutral ph. 15 Our previous report demonstrated a prolonged inhibitory effect in H. pylori-positive subjects, 2 and the present study also demonstrates a significantly greater inhibition of acid secretion at 23 h after dosing compared with omeprazole. This suggests that rabeprazole achieves greater efficacy by blocking more of the proton pumps following dosing. Previous studies in healthy human subjects have demonstrated that a significantly greater increase in 24-h intragastric ph is achieved with rabeprazole than with lansoprazole, pantoprazole, omeprazole and placebo (P ¼ 0.04). 6 In addition, rabeprazole was significantly superior to omeprazole at maintaining intragastric ph > 3.0 (69% vs. 59%, P < 0.01) and ph > 4.0 (60% vs. 51%, P < 0.05) after eight consecutive days of treatment. 16 The relationship between the chemical properties of rabeprazole and its clinical effectiveness might be explained by the properties of the covalent bond to the transmembrane regions of the proton pump. Rabeprazole demonstrated the fastest rate of inhibition of in vitro ATPase activity in gastric vesicles when compared with omeprazole, lansoprazole and pantoprazole. 15 Furthermore, rabeprazole demonstrated continued binding to several transmembrane domains after achieving 100% inhibition of both ATPase activity and acid transport. 15 These effects may account for the more potent and prolonged efficacy of rabeprazole reported in studies in humans. Rabeprazole demonstrated a significantly greater inhibition of peptone meal-stimulated gastric acid secretion with the first dose and on the eighth day of daily treatment compared with omeprazole in H. pylori-negative
6 1114 G. V. OHNING et al. subjects. Rabeprazole was able to achieve % of its maximal inhibitory effect after a single dose, demonstrating its rapid onset and potent ability to inhibit peptone meal-stimulated gastric acid secretion. These data suggest that rabeprazole is a highly effective treatment for peptic disorders, and that its antisecretory effect is near maximal with the first dose. ACKNOWLEDGEMENTS This work was supported by Eisai Inc., Teaneck, NJ, USA and Janssen Pharmaceutica Inc., Titusville, NJ, USA and, in part, by the UCLA Clinical Research Center (NIH MOI-RR-00865). REFERENCES 1 Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl. 3): Ohning GV, Barbuti RC, Kovacs TOG, et al. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric secretion in subjects with Heliobacter pylori infection. Aliment Pharmacol Ther 2000; 14: Fordtran JS, Walsh JH. Gastric acid secretion rate and buffer content of the stomach after eating. Results in normal subjects and in patients with duodenal ulcer. J Clin Invest 1973; 52: Maxwell V, Eysselein VE, Kleibeuker J, Reedy T, Walsh JH. Glucose perfusion intragastric titration. Dig Dis Sci 1984; 29: Williams MP, Sercombe J, Hamilton RE, et al. A placebocontrolled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy subjects. Aliment Pharmacol Ther 1998; 12: Pantoflickova D, Dorta G, Jornod P, Blum AL. Antisecretory activity of PPIs. Gut 2000; 47(Suppl. 3): A64(Abstract). 7 Londong W, Londong V, Cederburg C, et al. Dose response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterology 1983; 85: Sharma BK, Walt RP, Pounder RE, Gomes MD, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984; 25: Gardner JD, Perdomo C, Sloan S, et al. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 2002; 16: Cloud ML, Enas N, Humphries TJ, et al. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998; 43: Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicenter study. Aliment Pharmacol Ther 1999; 13: Baisley KJ, Tejura B, Morocutti A, Miller NM, Warrington S. Rabeprazole 20 mg is more potent than esomeprazole 20 mg in control of gastric ph in healthy volunteers. Am J Gastroenterol 2001; 96(Suppl. 1): S Wilder-Smith C, Claar-Nilsson C, Hasselgren G, Röhss K. Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD. Am J Gastroenterol 2001; 96(Suppl.): S Johnson P, Perdomo C, Barth J, Jokubaitis L. The benefit/risk profile of rabeprazole, a new proton pump inhibitor. Eur J Gastroenterol Hepatol 2000; 12: Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: Williams MP, Blanshard C, Millison J, et al. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Aliment Pharmacol Ther 2000; 14:
Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,
More informationReview article: pharmacology of esomeprazole and comparisons with omeprazole
Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 5 9. Review article: pharmacology of esomeprazole and comparisons with omeprazole J. DENT Department of Gastroenterology, Hepatology and General Medicine, Royal
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationEffects of rabeprazole, lansoprazole and omeprazole on intragastric ph in CYP2C19 extensive metabolizers
Aliment Pharmacol Ther 2002; 16: 1811 1817. doi:10.1046/j.0269-2813.2002.01348.x Effects of rabeprazole, lansoprazole and omeprazole on intragastric ph in CYP2C19 extensive metabolizers T. SAITOH*, Y.
More informationReview article: immediate-release proton-pump inhibitor therapy potential advantages
Aliment Pharmacol Ther 25; 22 (Suppl. 3): 25 3. Review article: immediate-release proton-pump inhibitor therapy potential advantages C. W. HOWDEN Division of Gastroenterology, Northwestern University Feinberg
More informationIntragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized, two-way crossover study
Aliment Pharmacol Ther 2005; 21: 963 967. doi: 10.1111/j.1365-2036.2005.02432.x Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily a randomized,
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationOral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric ph in healthy subjects
Alimentary Pharmacology & Therapeutics Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric ph in healthy subjects D. ARMSTRONG*, C. JAMES*, F. CAMACHO, Y.CHEN*,G.L.A.HORBAYà,
More informationSUMMARY INTRODUCTION. Accepted for publication 4 June 2004
Aliment Pharmacol Ther 24; 2: 899 97. doi: 1.1111/j.1365-236.24.2176.x Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way
More informationUnmet Needs in the Management of Gastroesophageal Reflux Disease
Unmet Needs in the Management of Gastroesophageal Reflux Disease Ronnie Fass MD Professor of Medicine Case Western Reserve University Chairman, Division of Gastroenterology and Hepatology Director, Esophageal
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationOmeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.
Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole
More informationA. Incorrect! Histamine is a secretagogue for stomach acid, but this is not the only correct answer.
Pharmacology - Problem Drill 21: Drugs Used To Treat GI Disorders No. 1 of 10 1. Endogenous secretagogues for stomach acid include: #01 (A) Histamine (B) Gastrin (C) PGE1 (D) A and B (E) A, B and C Histamine
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationtranslational physiology
J Appl Physiol 92: 427 434, 2002; 10.1152/japplphysiol.00956.2001. translational physiology Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration JERRY D. GARDNER, 1 ARTHUR
More informationOral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric ph in healthy subjects
Aliment Pharmacol Ther 2003; 18: 705 711. doi: 10.1046/j.1365-2036.2003.01743.x Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric in healthy subjects D. ARMSTRONG*,
More informationGERD: 2014 Dilemmas and Solutions. Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University
GERD: 2014 Dilemmas and Solutions Ronnie Fass MD, FACP Professor of Medicine Case Western Reserve University How to Maximize Your PPI Treatment? Improve compliance and adherance Fass R. Am J Gastroenterol.
More informationReview article: similarities and differences among delayed-release proton-pump inhibitor formulations
Aliment Pharmacol Ther 2005; 22 (Suppl. 3): 20 24. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations J. R. HORN* & C. W. HOWDEN *Department of Pharmacy,
More informationNexium 24HR. Tools and information for you and your pharmacy team NOW OTC FOR FREQUENT HEARTBURN. Consumer Healthcare Pfizer Inc.
NOW OTC FOR FREQUENT HEARTBURN w e N Nexium 24HR P H A R M A S S I S T K I T Tools and information for you and your pharmacy team 2014 Pfizer Inc. NXM041468 05/14 Q: What is the indication for Nexium 24HR
More informationRpts. GENERAL General Schedule (Code GE)
Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationAcid-suppressive drugs that
Pharmacology of acid suppression in the hospital setting: Focus on proton pump inhibition Joseph R. Pisegna, MD The more potent and longer-lasting inhibition of gastric acid secretion provided by proton
More informationA model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?
Alimentary Pharmacology and Therapeutics A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing? P. O. Katz*, D. A. Johnson
More informationFour-Day Bravo ph Capsule Monitoring With and Without Proton Pump Inhibitor Therapy
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1083 1088 Four-Day Bravo ph Capsule Monitoring With and Without Proton Pump Inhibitor Therapy IKUO HIRANO, QING ZHANG, JOHN E. PANDOLFINO, and PETER J. KAHRILAS
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More informationHeartburn is a common symptom among adults in
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:553 563 Early Heartburn Relief With Proton Pump Inhibitors: A Systematic Review and Meta-analysis of Clinical Trials KENNETH R. MCQUAID*, and LOREN LAINE
More informationGI Pharmacology. Dr. Alia Shatanawi 5/4/2018
GI Pharmacology Dr. Alia Shatanawi 5/4/2018 Drugs Used in Gastrointestinal Diseases Drugs used in Peptic Ulcer Diseases. Drugs Stimulating Gastrointestinal Motility &Laxatives. Antidiarrheal Agents. Drugs
More informationPharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole
Aliment Pharmacol Ther 2001; 15: 1563±1569. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole T. ANDERSSON*, K. ROÈ HSS, E.BREDBERG & M. HASSAN-ALIN *Clinical Pharmacology,
More informationOVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LOSEC AND ASSOCIATED NAMES (SEE ANNEX I)
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 21 SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE
More informationValidation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease
Volume 11 Number 4 2008 VALUE IN HEALTH Validation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease Ola Junghard, PhD, 1 Ingela Wiklund, PhD
More informationSystematic review of proton pump inhibitors for the acute treatment of re ux oesophagitis
Aliment Pharmacol Ther 2001; 15: 1729±1736. Systematic review of proton pump inhibitors for the acute treatment of re ux oesophagitis S. J. EDWARDS*, T. LIND & L. LUNDELLà *Outcomes Research, AstraZeneca,
More informationPublic Assessment Report. Scientific discussion. Rabeprazolnatrium Torrent Pharma. 10 mg and 20 mg gastro-resistant tablets. Rabeprazole sodium
Public Assessment Report Scientific discussion Rabeprazolnatrium Torrent Pharma 10 mg and 20 mg gastro-resistant tablets Rabeprazole sodium DK/H/1819/001-002/DC This module reflects the scientific discussion
More informationAlimentary Pharmacology & Therapeutics SUMMARY
Alimentary Pharmacology & Therapeutics Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayedrelease esomeprazole capsules on nocturnal
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationPthaigastro.org. Evolution of antisecretory agents. History. Antacids and anticholinergic drugs
Evolution of antisecretory agents uthapong Ukarapol, MD. Division of Gastroenterology Chiang Mai University istory 1823- Prout discovered gastric hydrochloric acid 1875- eidenhain and 1893- Golgi identified
More informationOptimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI
Optimal Management of GERD with Dexlansoprazole - Extended plasma concentration and dosing flexibility with a dual delayed release PPI Jun Heng Lee, M.D. Samsung Medical Center, Sungkyunkwan University
More informationDrug Class Review Proton Pump Inhibitors
Drug Class Review Proton Pump Inhibitors Evidence Tables April 2009 Update 4: May 2006 Update 3: May 2005 Update 2: April 2004 Update 1: April 2003 Original Report: November 2002 The literature on this
More informationReview article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication
Aliment Pharmacol Ther 2004; 19 (Suppl. 1): 66 70. Review article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication G. HOLTMANN* & C. W. HOWDEN
More informationSUMMARY INTRODUCTION. Aliment Pharmacol Ther 2000; 14: 1595±1603. Accepted for publication 14 August 2000
Aliment Pharmacol Ther 2000; 14: 1595±1603. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal re ux disease (GERD)
More informationProton Pump Inhibitors. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors
More informationPRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW
PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related
More informationEMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated
EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both
More informationSUMMARY INTRODUCTION. Accepted for publication 14 January 2004
Aliment Pharmacol Ther 2004; 19: 655 662. doi: 10.1111/j.1365-2036.2004.01893.x, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric ph and comparison with esomeprazole
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationClinical effectiveness of a new antacid chewing gum on heartburn and oesophageal ph control
Aliment Pharmacol Ther 2002; 16: 2029 2035. doi:10.1046/j.0269-2813.2002.01380.x Clinical effectiveness of a new antacid chewing gum on heartburn and oesophageal ph control K. L. COLLINGS*, S. RODRIGUEZ-STANLEY*,
More informationComparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcerða European multicentre study
Aliment Pharmacol Ther 1998; 12: 789±795. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcerða European multicentre study C. P. M. DEKKERS 1,J.A.BEKER 2, B. THJODLEIFSSON
More informationFARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI
FARMACI E ALTE VIE DIGESTIVE NELL ANZIANO: UTILITÀ E LIMITI Edoardo V. Savarino, MD, PhD Professor of Gastroenterology Department of Surgery, Oncology and Gastroenterology University of Padua Italy COMMON
More informationEsomeprazole Pharmacokinetics in Patients with Cirrhosis and Healthy Controls ABSTRACT
Original Article 21 Esomeprazole Pharmacokinetics in Patients with Cirrhosis and Healthy Controls Kanlayanee Archasantisuk, M.Sc.* Sombat Treeprasertsuk, M.D., M.Sc.** Mayyuree Tantisira, Ph.D.** Arun
More informationOur gut reactions to food or, gut reactions - to food
Key concepts in Digestion. Our gut reactions to food or, gut reactions to food Prof. Barry Campbell Cellular & Molecular Physiology email: bjcampbl@liv.ac.uk http://pcwww.liv.ac.uk/~bjcampbl Swallowing
More informationGASTROESOPHAGEAL reflux
ORIGINAL INVESTIGATION Lansoprazole Compared With Ranitidine for the Treatment of Nonerosive Gastroesophageal Reflux Disease Joel E. Richter, MD; Donald R. Campbell, MD; Peter J. Kahrilas, MD; Bidan Huang,
More informationORIGINAL ARTICLES ALIMENTARY TRACT. A Randomized, Comparative Study of Three Doses of AZD0865 and Esomeprazole for Healing of Reflux Esophagitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:1385 1391 ORIGINAL ARTICLES ALIMENTARY TRACT A Randomized, Comparative Study of Three Doses of AZD0865 and Esomeprazole for Healing of Reflux Esophagitis
More informationAppropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationResults. Subject Disposition and Demographics Of 37 enrolled subjects, 23 (62.2%) completed the study
Poster 5-20 Effect of Gastric ph on the Bioavailability of in Healthy Subjects James Longstreth, PhD, Marijke H. Adams, PharmD, PhD, 2 Vasi Sperry, PhD, 3 Dan Kajdasz, PhD, 3 Carol R. Reed, MD 3 Longstreth
More informationDepartment of Gastroenterology, Kocaeli University School of Medicine, Kocaeli, Turkey 2
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc ph in extensive metabolizer patients with gastroesophageal reflux disease
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationOptimizing Medical Therapy for Gastroesophageal Reflux Disease: State of the Art Philip O. Katz, MD
TREATMENT UPDATE Optimizing Medical Therapy for Gastroesophageal Reflux Disease: State of the Art Philip O. Katz, MD Department of Medicine, Graduate Hospital, Philadelphia, PA Potential interventions
More informationMany patients with gastroesophageal reflux
... HEALTH ECONOMICS... Efficacy and Cost Effectiveness of Lansoprazole Versus Omeprazole in Maintenance Treatment of Symptomatic Gastroesophageal Reflux Disease Eva Vivian, PharmD; Anthony Morreale, PharmD,
More informationOSPAP Programme. Gastrointestinal Drugs. Dr. Adrian Moore Dale
PAP Programme Dr. Adrian Moore Dale 1.03 Adrian.Moore@sunderland.ac.uk 0191 5152554 lide 1 of 26 PAP MPM14 Acid-Related Pathophysiology The stomach secretes: ydrochloric acid (Cl) aids digestion and also
More informationChapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases
Chapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases p1009 DRUGS USED IN ACID-PEPTIC DISEASES 1. classification of drugs 2. agents that reduce intragastric acidity Antacids,H 2 antagonists,proton
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationProton Pump Inhibitors- Questions & Controversies. Farah Kablaoui, PharmD, BCPS, BCCCP
Proton Pump Inhibitors- Questions & Controversies Farah Kablaoui, PharmD, BCPS, BCCCP Disclosure Information Proton Pump Inhibitors: Questions & Controversies Farah Kablaoui I have no financial relationship
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationHelicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease
Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency
More informationDavid A. Peura 1,5*, Anne Le Moigne 2, Heather Wassel 3 and Charles Pollack 4
Peura et al. BMC Gastroenterology (2018) 18:69 https://doi.org/10.1186/s12876-018-0790-2 RESEARCH ARTICLE Open Access Sustained efficacy following resolution of frequent heartburn with an over-thecounter
More informationcompared with ranitidine
1458 Gut 1993; 34:1458-1462 CLINICAL TRIAL Department of Therapeutics, University Hospital, Nottingham C J Hawkey R G Long Rotherham District General Hospital, Rotherham K D Bardhan Ninewelis Hospital,
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
PROTON PUMP INHIBITORS, NON-PREFERRED FORMS: ACIPHEX (rabeprazole sodium EC) oral tablet ACIPHEX SPRINKLE (rabeprazole sodium DR) oral capsule ESOMEPRAZOLE STRONTIUM (esomeprazole strontium DR) oral capsule
More informationThe effects on intragastric acidity of per-gastrostomy administration of an alkaline suspension of omeprazole
Aliment Pharmacol Ther 1999; 13: 1091±1095. The effects on intragastric acidity of per-gastrostomy administration of an alkaline suspension of omeprazole V. K. SHARMA, R. VASUDEVA & C. W. HOWDEN Division
More informationIs Rabeprazole A Safe Treatment for Gastroesophageal Reflux Disease in Children Ages 1-16 years?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Rabeprazole A Safe Treatment for Gastroesophageal
More informationIntragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers
Intragastric ph With Oral vs Intravenous Bolus Plus Infusion Proton- Pump Inhibitor Therapy in Patients With Bleeding Ulcers LOREN LAINE, ABBID SHAH, and SHAHROOZ BEMANIAN Division of Gastrointestinal
More informationThe usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.
Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs
More informationH o w d o e a c t. y o u r a c i
H o w d o e a c t p a n t o p r a b r e a k d y o u r a c i Pantoprazole Sodium is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole is a lipophilic,
More informationNexium 24HR Pharmacy Training
Nexium 24HR Pharmacy Training Your pharmacist's advice is required. Always read the label. Use only as directed. If symptoms persist, consult your doctor/ healthcare professional. Pfizer Consumer Healthcare
More informationeffect on daytime acidity
Gut, 1989, 3, 59-599 Do H2 receptor antagonists have to be given at night? A study of the antisecretory profile of SKF 982, a new H2 receptor antagonist which has a profound effect on daytime acidity S
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Evidence Tables July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May 2005
More informationEU RISK MANAGEMENT PLAN (EU RMP)
EU RISK MANAGEMENT PLAN (EU RMP) Active substance(s) (INN or common name): Esomeprazole Pharmaco-therapeutic group (ATC Code): A02B C05 Name of Marketing Authorisation Holder or Applicant: Strength and
More informationDisclosures. Proton Pump Inhibitors Deprescribing? Deprescribing PPI Objectives. Deprescribing. Proton Pump Inhibitors (PPI) 5/28/2018.
Proton Pump Inhibitors Deprescribing? None Disclosures Chad Burski, MD Assistant Professor of Medicine UAB Gastroenterology Deprescribing PPI Objectives AR Why? Who? How? The mechanism of action of Proton
More informationIntroduction ORIGINAL ARTICLE. Vijayalakshmi S. Pratha 1, Thomas McGraw 2 & William Tobin 3. Abstract
ORIGINAL ARTICLE A randomized, crossover pharmacodynamic study of immediate-release omeprazole/sodium bicarbonate and delayed-release lansoprazole in healthy adult volunteers Vijayalakshmi S. Pratha 1,
More informationProton Pump Inhibitor De-prescribing Guidance
Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page
More informationPACKAGE INSERT. 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole sodium, equivalent
PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) PARIET 10 mg tablets PARIET 20 mg tablets COMPOSITION 10mg: Each enteric-coated delayed release tablet contains 10 mg of rabeprazole
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationEsomeprazole versus omeprazole for the eradication of Helicobacter pylori infection
International Journal of Community Medicine and Public Health Ageeli R et al. Int J Community Med Public Health. 2018 Jul;5(7):2686-2691 http://www.ijcmph.com pissn 2394-6032 eissn 2394-6040 Original Research
More informationPolicy Evaluation: Proton Pump Inhibitors (PPIs)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAlginates Extended Abstract
Alginates Extended Abstract III) Clinical practice guidelines: DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationThe Association and Clinical Implications of Gastroesophgeal Reflux Disease and H. pylori
The Association and Clinical Implications of Gastroesophgeal Reflux Disease and H. pylori Maxwell M. Chait The relationship between GERD and H. pylori is complex and negatively associated with important
More informationMeasuring and Evaluating Indicators of Appropriate Prescribing in Older. Populations
HRB PhD Scholar Division of Population Health Sciences RCSI Measuring and Evaluating Indicators of Appropriate Prescribing in Older Cost-Effective Proton Pump Populations Potential Strategies for more
More informationOverview of digestion or, gut reactions - to food
Key concepts in Digestion. Indigestion module Overview of digestion or, gut reactions - to food Prof. Barry Campbell Gastroenterology Cellular & Molecular Physiology e-mail: bjcampbl@liv.ac.uk http://pcwww.liv.ac.uk/~bjcampbl
More informationPage 1 of 5 Official reprint from UpToDate www.uptodate.com 2017 UpToDate Patient education: Acid reflux (gastroesophageal reflux disease) in adults (The Basics) Written by the doctors and editors at UpToDate
More informationPPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)
Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations
More informationNew Therapeutic Options in the Treatment of GERD and Other Acid-Peptic Disorders
...SYMPOSIUM PROCEEDINGS... New Therapeutic Options in the Treatment of GERD and Other Acid-Peptic Disorders Based on a presentation by Duane D. Webb, MD, FACG Presentation Summary Gastroesophageal reflux
More informationOptimal Drugs for ICU Stress Ulcer Prophylaxis: Other. Grand Rounds Monday August 9, 2010 Teresa Jones R2
Optimal Drugs for ICU Stress Ulcer Prophylaxis: Other Grand Rounds Monday August 9, 2010 Teresa Jones R2 Outline Options besides PPIs Comparison to PPIs Negative Effects of PPIs Conclusion Do we really
More informationAll Indiana Medicaid Prescribers and Pharmacy Providers
P R O V I D E R B U L L E T I N BT200148 NOVEMBER 28, 2001 To: All Indiana Medicaid Prescribers and Pharmacy Providers Subject: Note: The information in this bulletin regarding prior authorization payment
More informationEffective Health Care
Effective Health Care Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease Executive Summary Background Gastroesophageal reflux disease (GERD), defined as weekly heartburn
More informationOverview of digestion or, gut reactions - to food
1 Key concepts in Digestion. Indigestion module Overview of digestion or, gut reactions to food Prof. Barry Campbell Gastroenterology Cellular & Molecular Physiology email: bjcampbl@liv.ac.uk http://pcwww.liv.ac.uk/~bjcampbl
More informationModule 2 Heartburn Glossary
Absorption Antacids Antibiotic Module 2 Heartburn Glossary Barrett s oesophagus Bloating Body mass index Burping Chief cells Colon Digestion Endoscopy Enteroendocrine cells Epiglottis Epithelium Absorption
More information